NCT05884255View on ClinicalTrials.gov

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

PHASE3RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

October 31, 2030

Conditions
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Interventions
DRUG

Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide

Lutetium (177Lu) Oxodotreotide Injection combined with standard-dose long-acting Octreotide

DRUG

long-acting Octreotide.

High-dose long-acting Octreotide.

Trial Locations (1)

300060

RECRUITING

Tianjin University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY